세계 난소암 시장 – 2023-2030

Overview
Global Ovarian Cancer Market reached US$ 1.8 billion in 2022 and is expected to reach US$ 8.2 billion by 2030 growing with a CAGR of 23.7% during the forecast period 2023-2030.
Ovarian cancer is a deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.
The main treatments for ovarian cancer are Surgery and chemotherapy. The treatment depends on several factors, including cancer stage and grade. Ovarian cancer can only be definitively diagnosed through a surgical biopsy. Surgical debulking, radiotherapy, and chemotherapy remain the mainstream treatment modalities.
Furthermore, monoclonal antibodies are considered both immunotherapy agents and targeted therapies for ovarian cancer. Checkpoint inhibitors are also used in the treatment. Rising advancements in cancer research, the increasing prevalence of ovarian cancer among females, and increasing clinical trials are a few factors that drive the market in the forthcoming period.
Dynamics
Increasing Endometriosis Cases among Females
Endometriosis increases the risk of developing epithelial ovarian cancer (EOC). Younger women diagnosed with endometriosis were at increased risk of developing endometriosis-associated ovarian carcinoma (EOAC). Females with an endometriosis history are more prone to ovarian cancer, as delayed diagnosis of endometriosis can directly lead to tumor formation, which leads to severe implications.
According to the World Health Organisation's March 2023 issue, endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. There is currently no known cure for endometriosis, and treatment is usually aimed at controlling symptoms.
Access to early diagnosis and effective endometriosis treatment is essential but limited in many settings, including in low- and middle-income countries. Ovarian cancer remains the deadliest type of gynecological cancer in women. Nearly 1 in 76 women are at risk of developing ovarian cancer in their lifetime; endometriosis increases this slightly to 1 in 5.
Rising Pipeline Drugs
The US FDA recently granted accelerated approval to our lead product for treating ovarian cancer, and we have several novel ADCs in development in our pipeline. Major drug developers are investigating their lead agents in combination therapies to gradually progress into the front line of ovarian cancer treatment to replace chemotherapies soon.
MIRASOL, Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer (Randomized Confirmatory Trial) positive top-line data reported MAY 2023. Genentech’s Avastin (bevacizumab) and poly ADP-ribose polymerase (PARP) inhibitors. AstraZeneca’s Lynparza (olaparib), Tesaro’s Zejula (niraparib), and Clovis Oncology’s Rubraca (rucaparib) are paving the way for more targeted therapies and novel agents with new mechanisms of action (MOAs). GLORIOSA, doublet with Mirvetuximab & Bevacizumab Maintenance in FRα-High Platinum-Sensitive Ovarian Cancer.
Drug Resistance
Drug Resistance for ovarian cancer treatment is increasing because of the tumor cell resistance to the chemotherapeutic drugs in some or other pathways. The traditional treatment for ovarian cancer is platinum-based chemotherapy (carboplatin or cisplatin) in combination with paclitaxel, and it has remained the same for the past two decades. Most patients are initially responsive to these treatments; however, relapse occurs in around 80% of women due to platinum resistance. One of the metabolic pathways is a crucial driver of metastasis and drug resistance in many different cancers, including ovarian cancer. Discoveries in novel resistance mechanisms and approaches to overcome drug resistance through nanomedicine shortly.
Segment Analysis
The global is segmented based on type, treatment type, end user, and region.
The Chemotherapy Segment Accounted for Approximately 54.3% of the Market Share
Epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are phase III randomized study evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer,
A phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early degeneration (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.
Geographical Analysis
North America accounted for Approximately 39.1% of the Market Share in 2022
North America is predicted to command the global ovarian cancer market since North America has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 78. Her lifetime chance of dying from ovarian cancer is about 1 in 108. The American Cancer Society estimates for ovarian cancer in the United States for 2023 over 20,000 women will receive a new diagnosis of ovarian cancer, and about 13,270 women will die from ovarian cancer.
Clinical trials are essential to improving cancer treatment, especially in highly lethal cancers like ovarian cancer. Major cancer organizations, including the National Comprehensive Cancer Network, American Society of Clinical Oncology, and Association of Community Cancer Centers, endorse that all cancer patients should consider and have the opportunity to participate in clinical trials. Black or African American patients comprised 8% of participants in clinical trials despite making up 14% of the US population. Similarly, Hispanics comprised 11% of participants in clinical trials but 18% of the US population.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global ovarian cancer market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity.
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of cancer-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market.
By Type
• Epithelial Ovarian Cancer
• Germ Cell Ovarian Cancer
• Stromal Cell Ovarian Cancer
• Small Cell Ovarian Cancer
• Others
By Treatment Type
Diagnosis
• Blood Tests
• Imaging Tests
• Surgical Evaluation
• Others
Drug/Therapy
• Targeted Therapy
o Small molecule Drugs
o Monoclonal Antibodies
o Others
• Immunotherapy
• Chemotherapy
o PARP Inhibitors
o Angiogenesis Inhibitors
o PD-L1 Inhibitors
o Others
• Others
By End User
• Hospitals and Clinics
• Cancer Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In January 2023, TYVYT® has been included in the NRDL for two additional indications including gastric cancer and esophageal cancer. TYVYT® is the first and the only PD-1 inhibitor for gastric cancer in the NRDL, as well as the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL.
• In November 2022, ImmunoGen received FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer. The approval of ELAHERE is significant for patients with FRα-positive platinum-resistant ovarian cancer, which is characterized by limited treatment options and poor outcomes.
• In November 2022, Roche received FDA approval for VENTANA FOLR1 RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE. ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by ImmunoGen, Inc
Competitive Landscape
The major global players in the ovarian cancer market include AstraZeneca, Roche, GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck among others.
Why Purchase the Report?
• To visualize the global ovarian cancer market segmentation based on type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ovarian cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global ovarian cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies